Skip to main content

Table 3 Level of 25(OH)D in Healthy Subjects and Patients with malabsorption syndrome after 30 day administration of vitamin D3 buccal spray and soft gelatin capsule

From: A randomized two way cross over study for comparison of absorption of vitamin D3 buccal spray and soft gelatin capsule formulation in healthy subjects and in patients with intestinal malabsorption

Parameters Mean baseline value in ng/ml Mean value in ng/ml after 30 day of treatment Difference of mean Percentage mean increase from baseline
Healthy Subjects
Soft gelatin Capsule Formulation
 Mean 18.69 ± 5.88 22.75 ± 6.75 4.06 21.72 %
 Range 9.25, 30.05 12.75, 35.52 2.5, 5.6 15.36, 37.79
 n 13 13 13 13
 95 % CI 15.14 to 22.24 18.67 to 24.42 3.41 to 4.71 16.42 to 24.42
Buccal Spray Formulation
 Mean 18.91 ± 4.3 26.91 ± 5.72 7.995 42.99 %
 Range 13.36, 26.82 19.6, 38.5 4.5, 11.67 29.21, 68.71
 n 13 13 13 13
 95 % CI 16.31 to 21.51 23.45 to 30.36 6.86 to 9.13 37.19 to 48.79
Patients with intestinal malabsorption syndrome
Soft gelatin Capsule Formulation
 Mean 11.01 ± 6.43 14.97 ± 9.01 3.965 36.02 %
 Range 2.9, 26.5 4.6, 36.89 1.06,10.39 24.62,58.73
 n 13 13 13 13
 95 % CI 7.12 to 14.89 9.52 to 20.42 2.37 to 5.56 30.42 to 41.62
Buccal Spray Formulation
 Mean 10.01 ± 4.29 20.47 ± 7.89 10.46 117.8 %
 Range 4.6, 18.85 9.8, 34.64 4.25, 27.44 61.31,381.1
 n 13 13 13 13
 95 % CI 7.42 to 12.6 15.7 to 25.24 6.89 to 14.03 64.71 to 170.8